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Résumé en
anglais
Metastatic melanoma has been described as a highly aggressive cancer with low
sensibility to chemotherapeutic agents. New types of drug, such as metal-based drugs
(ferrocifens) have emerged and could represent an alternative for melanoma treatment
since they show interesting anticancer potential. Furthermore, molecular analysis has
evidenced the role of apoptosis in the low sensibility of melanomas and especially of
the key regulator, Bcl-2. The objective of this study was to combine two strategies in
the same lipid nanocapsules (LNCs): i) gene therapy to modulate anti-apoptotic
proteins by the use of Bcl-2 siRNA, and ii) ferrocifens as a new type of anticancer
agent. The efficient gene silencing with LNCs was verified by the specific extinction of
Bcl-2 in melanoma cells. The cellular toxicity of ferrocifens (ferrociphenol (FcDiOH) or
Ansa-FcDiOH) was demonstrated, showing higher efficacy than dacarbazine.
Interestingly, the association of siBcl-2 LNCs with Ansa-FcDiOH demonstrated a
significant effect on melanoma cell viability. Moreover, the co-encapsulation of siRNA
and ferrocifens was successfully performed into LNCs for animal experiments. A
reduction of tumor volume and mass was proved after siBcl-2 LNC treatment and Ansa-
FcDiOH LNC treatment, individually (around 25%). Finally, the association of both
components into the same LNCs increased the reduction of tumor volume to about
50% compared to the control group. In conclusion, LNCs appeared to provide a
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